文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster.

作者信息

Wagenhäuser Isabell, Reusch Julia, Gabel Alexander, Krone Lukas B, Kurzai Oliver, Petri Nils, Krone Manuel

机构信息

Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.

Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, Germany.

出版信息

Clin Microbiol Infect. 2023 Apr;29(4):554-556. doi: 10.1016/j.cmi.2023.01.008. Epub 2023 Jan 16.

DOI:10.1016/j.cmi.2023.01.008
PMID:36657489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9841732/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec33/9841732/14941bdd4131/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec33/9841732/14941bdd4131/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec33/9841732/14941bdd4131/gr1_lrg.jpg

相似文献

[1]
Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster.

Clin Microbiol Infect. 2023-4

[2]
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.

MMWR Morb Mortal Wkly Rep. 2022-11-4

[3]
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.

MMWR Morb Mortal Wkly Rep. 2022-11-11

[4]
Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.

J Med Econ. 2023

[5]
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.

MMWR Morb Mortal Wkly Rep. 2023-1-13

[6]
Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.

Emerg Infect Dis. 2022-6

[7]
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.

MMWR Morb Mortal Wkly Rep. 2023-1-27

[8]
Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.

Front Immunol. 2023

[9]
Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.

EBioMedicine. 2023-2

[10]
Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries in Japan.

Clin Infect Dis. 2023-1-6

引用本文的文献

[1]
Intersecting SARS-CoV-2 spike mutations and global vaccine efficacy against COVID-19.

Front Immunol. 2025-3-7

[2]
The Global Burden of Absenteeism Related to COVID-19 Vaccine Side Effects Among Healthcare Workers: A Systematic Review and Meta-Analysis.

Vaccines (Basel). 2024-10-19

[3]
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults.

Vaccines (Basel). 2023-11-11

[4]
De Novo ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis After COVID-19 mRNA Vaccination: A Case Report.

J Korean Med Sci. 2023-10-23

[5]
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.

EBioMedicine. 2023-5

[6]
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines.

Vaccines (Basel). 2023-3-14

[7]
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.

Pathogens. 2023-2-2

[8]
Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines.

Biomedicines. 2023-2-3

本文引用的文献

[1]
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.

N Engl J Med. 2023-2-9

[2]
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination.

Eur Respir J. 2023-1

[3]
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.

N Engl J Med. 2023-1-12

[4]
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.

JAMA Netw Open. 2022-9-1

[5]
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.

N Engl J Med. 2022-10-6

[6]
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.

N Engl J Med. 2022-4-21

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索